Multiple myeloma is a hematological neoplasm characterized by the accumulation of clonal plasma cells in the bone marrow. Its frequent relapse following achievement of clinical remissions implicates the existence of therapy-resistant myeloma-initiating cells. 
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Multiple myeloma is a hematological neoplasm characterized by the accumulation of clonal plasma cells in the bone marrow. Its frequent relapse following achievement of clinical remissions implicates the existence of therapy-resistant myeloma-initiating cells. To date, results on the identity of myeloma-initiating cells have differed. Here, we prospectively identified a myeloma-initiating population by fractionating and transplanting patient bone marrow cells into human bone-bearing immunocompromised mice.
Xenotransplantation of fractionated CD138
þ /CD38 high cells from 40% of patients (8/20) 1 During the last decade, distinct tumor-initiating cells have been identified from various cancer types. [2] [3] [4] [5] [6] [7] [8] [9] [10] Recent studies demonstrated that these tumor-initiating cells are relatively resistant to chemotherapeutic agents 4, 6 and radiotherapy 11 compared with their non-tumor-initiating cell counterparts, strongly implicating their role in tumor relapse, maintenance and metastasis. Multiple myeloma is a plasma cell neoplasm characterized by the accumulation of clonal plasma cells in the bone marrow. In spite of advances in treatment, recent studies demonstrate that the majority of patients with multiple myeloma relapse after initial responses to therapies. 12 These results suggest the presence of therapy-resistant myeloma-initiating cells. The fact that the malignant cells are clonal plasma cells has led some to postulate that the tumor cells may arise from post-germinal center B-lineage cells such as memory B cells, plasmablasts or plasma cells.
Functional demonstration of tumor-initiating cells requires serial xenotransplantation of candidate primary patient cancer cell populations into immunocompromised mice. Successful xenotransplantation of patient myeloma cells has been reported for the last two decades. [13] [14] [15] [16] However, these studies using severe combined immunodeficiency (SCID), NOD/SCID or SCID-hu lacked consistency, raising questions on the relevance of the various mouse models in use. Recently, two immunocompromised mouse strains, NOD/SCID/common cytokine receptor g chain-deficient (NSG) and recombinase-activating gene 2/common cytokine receptor g chain-deficient (RAG2 À /gc À ) mice, which lack natural killer, B and T cells, were reported to increase the engraftment of human hematopoietic cells [17] [18] [19] and solid cancer cells. 8, 20 Whether the engraftment of patient myeloma cells in these improved immunocompromised mice is reliable has not been tested yet. In spite of the poor engraftment characteristics of patient myeloma cells in mice, Matsui et al. 14, 21 reported that CD138 À CD34 À bone marrow cells (from 1 of 4 patients) and CD19 þ CD27 þ peripheral blood cells (4/4 patients), but not CD138 þ plasma/myeloma cells, engrafted in NOD/SCID mice, as demonstrated by the repopulation of CD138 þ myeloma cells. In addition, the elimination of CD20 þ B cells with rituximab abolished engraftment of NOD/SCID mice with myeloma cells, suggesting that memory B cells are myeloma-initiating cells. Meanwhile, Yaccoby et al., 22 Yata et al., 23 and Huang et al. 24 groups reported that CD45 low/ À CD38 high and CD138 þ plasma cells successfully engrafted mice containing human or rabbit fetal bone grafts even though they did not investigate the serial engraftment ability of the myeloma cells.
These differing results leave the identity of myeloma-initiating cells unclear.
Here, we examined the engraftment ability of cells from multiple myeloma patients in immunocompromised RAG2 À /gc À , NOD/SCID and NSG mice that either had or lacked previously placed subcutaneous human fetal bone grafts. Transplantations of unfractionated and fractionated patient bone marrow cells demonstrate the importance of the human bone marrow microenvironment in xenografting multiple myeloma and reveal a (CD19 À or CD45 low/ À ) CD38 high /CD138 þ myeloma-initiating population in multiple myeloma patients.
MATERIALS AND METHODS

Preparation of patient bone marrow cells
Clinical bone marrow samples were obtained between October 2007 and June 2011 from patients with multiple myeloma that was newly diagnosed, relapsed or with residual diseases (Supplementary Table 1 ). The samples were obtained according to protocols (eprotocol no.: 9718) approved by the Institutional Review Board of the Stanford University School of Medicine. Mononuclear cells were isolated using Ficoll-Paque (Pharmacia, Piscataway, NJ, USA). The mononuclear cells were directly transplanted into mice before or after fractionation, or they were frozen for future studies.
Mice
Experiments using NOD/SCID, NSG and RAG2
À /gc À mice were approved by the Stanford University School of Medicine's Administrative Panel on Laboratory Animal Care Committee (protocol no.: 16886). The mice were bred and maintained in the Stanford University animal care facility. Mice aged 6-10 weeks without human fetal bone grafts received 280 rad (for NOD/SCID and NSG) or 400 rad (for RAG2 À /gc À ) irradiation using an X-ray irradiator (Faxitron Bioptics, Lincolnshire, IL, USA) before intravenous or intrafemoral transplantation of cells. The mice were anesthetized with isofluorane and injected with myeloma cells via the retro-orbital venous complex or directly into the femur.
Human bone-bearing NOD/SCID, NSG and RAG2 À /gc À mice were generated as previously reported. [25] [26] [27] Briefly, femurs, tibias and fibulas of 17-to 19-gestational-week-old human fetuses (Advanced Bioscience Resources, Alameda, CA, USA) were cleaned, cut into fragments (B5 Â 5 Â 10 mm), and implanted subcutaneously into 6-8-week-old mice. After 6 weeks, myeloma cells or bone marrow cells in a final volume of 25-50 ml of phosphate-buffered saline supplemented with 25% Matrigel (basement membrane; BD Biosciences, San Jose, CA, USA) were transplanted directed into the human bone grafts. The engraftment of human cells was determined using only mice that lived at least for 2 months after human cell transplantation to avoid misinterpretations by temporary survival of myeloma cells. 0 ) genes, respectively. In addition, allele-specific oligonucleotides were designed followed by PCR and subsequent sequencing of immunoglobulin genes. We did not detect EBNA2 expression in patient bone marrow samples in spite of the expression of EBNA2 in an Epstein-Barr virus-positive cell line, ARH77 (a kind gift from Ronald Levy, MD, Stanford University).
The expression of Pax5, CD19 and Blimp-1 was determined in cDNA of patient myeloma cells and xenograft cells by real-time RT-PCR and normalized to glyceraldehyde-3-phosphate dehydrogenase. The following primers were applied: Pax5 (forward:
0 ) and glyceraldehyde-3-phosphate dehydrogenase (forward:
Immunohistochemistry and histology
Human bone grafts were recovered from bone-bearing mice, fixed, decalcified, frozen in OCT (Tissue-Tek, Sakura Finetek USA, Inc., Torrance, CA, USA), and cryo-sectioned using a cryotome (Microm HM550, ThermoFisher Scientific, Waltham, MA, USA). Tissue sections were hybridized with anti-human human leukocyte antigens-A,B,C (G46-2.6, BD Biosciences) and anti-H-2K d (34-1-2S, eBioscience) antibodies, followed by hybridization with secondary antibodies conjugated with AlexaFluor 594 or AlexaFluor 488 (Molecular Probes, Invitrogen). The signal was detected using a Leica DMI6000B fluoromicroscope (Leica Microsystems GmbH, Wetzlar, Germany). In addition, myeloma cells and xenograft cells were identified morphologically following Wright-Giemsa staining (Sigma-Aldrich, St Louis, MO, USA) of cytospin slide preparations. Figure 1a) . In addition, the expression of CD56 on CD38 high /CD138 þ cells confirmed that the CD138 þ /CD38 high cells enrich for myeloma cells (Supplementary Figure 1b) .
RESULTS
Separation
Immunocompromised mice, RAG2 À /gc À and NSG, were not engrafted with bone marrow cells from myeloma patients A xenotransplantation mouse model that is faithfully engrafted with myeloma cells from patients is a prerequisite for studying myeloma-initiating cells. Previous studies reported that SCID and NOD/SCID mice can be engrafted with patient myeloma cells. 13, 14, 16, 22, 24, 28 Here, we investigated whether more severely immunocompromised, RAG2
À /gc À mice and NSG mice can reliably be engrafted with patient B and/or plasma cells injected either intravenously (14 samples into 44 mice) or intrafemorally (8 samples into 27 mice). As shown in Table 1 Immunocompromised mice with human fetal bone grafts were efficiently engrafted with patient B and plasma cells To provide the mice with a human bone marrow microenvironment in which myeloma/plasma cells typically reside, we grafted human fetal bone into NOD/SCID, NSG and RAG2 À /gc À mice. We then repeated the experiment described above whereby patient bone marrow cells were injected into the human bone grafts of these mice, then engraftment was assessed (Table 1) . In all, 12 of 31 patient samples led to the production of human antibodies detected in the serum of the mice, and 20/31 samples resulted in the repopulation of CD19 þ or CD138 þ B-lineage cells within the human bone grafts. These data indicate that immunocompromised mice with human fetal bone grafts can reliably engraft human CD19 þ or CD38 high /CD138 þ B-lineage cells. The markedly enhanced ability of human bone grafts to support patient B-lineage cell engraftment was confirmed by performing parallel evaluation of engraftment potential of bone marrow cells from three selected myeloma patients (M04, M12 and M19). Whole-or fractionated-bone marrow cells from these patients successfully engrafted human bone-bearing immunocompromised mice after transplantation into the human bone grafts while the patient cells did not engraft human bone-free immunocompromised mice after either intravenous or intrafemoral transplantation. A representative result of transplantation from patient M04 is shown in Supplementary Table 2 . These results support the hypothesis that human bone-bearing mice can be efficiently engrafted with human bone marrow B-lineage cells of multiple myeloma patients.
Human fetal bone marrow microenvironment is required for the survival and proliferation of human B-lineage cells We examined the microenvironment of grafted fetal bone in mice. A representative bone graft at 7 months after implantation shows that the human bone grafts grew in immunocompromised mice (Figure 1a) , maintaining bone marrow architecture (Figure 1b) and containing both human and mouse cells (Figure 1c) . Immunostaining, followed by microscopic and flow cytometric analyses, indicated that mouse CD45 þ cells infiltrated the human bone grafts. To examine whether the human bone marrow microenvironment is required for myeloma cell survival, we implanted two human fetal bone pieces in RAG2 À /gc À mice and then transplanted CD138 þ patient bone marrow cells (Figure 1d ) or CD138 þ passaged xenograft cells derived from patient primary myeloma cells (Figure 1e ) into one of the two human bone grafts (arrows). After 4-6 months, human CD138 þ cells were detected in both bone pieces, implying the migration of myeloma cells from one human bone (human bone 1) to another (human bone 2). However, we did not detect human cells in mouse bone, spleen or peripheral blood, indicating that the human bone microenvironment is significantly better in supporting the survival and growth of patient myeloma cells. 
Enrichment of myeloma-initiating cells using CD138
þ and/or CD38 high markers
We investigated the clonality of B and plasma cell xenografts to determine whether or not they were derived from patient myeloma cells (representative results seen in Figure 2d and (Figures 1d and 2a) . We observed the expansion/ proliferation of CD138 þ xenograft cells in the mice, even though the proliferation rate differed. In addition, two of nine xenografts derived from unfractionated bone marrow cells were CD138 þ . Hematopoietic stem cell engraftment in NSG mice: mice repopulated human B, T and myeloid cells.
f Three samples were transplanted both intravenously and intrafemorally.
Xenotransplantable patient myeloma cells from patients D Kim et al
In addition, two patient samples (M24 and M53) generated palpable tumor masses in and around the bone grafts and their tumor cells were successfully transferred to secondary fetal bone-bearing immnocompromised recipient mice (Figure 1e and Supplementary Figure 2) . The tumor cells were CD138 low/ þ
CD19
À cells (Figure 2e ) and produced monoclonal immunoglobulin light chains. Quantitative RT-PCR of the serially transplantable xenografts as well as two myeloma cell lines, RPMI8226 and NCI H929, indicated that a master transcription factor of B cells, Pax5 transcript was not detected in either xenograft or in myeloma cell lines while a master transcription factor of plasma cells, Blimp-1 transcript was detected (Figure 2f) , confirming the lack of B cells in transplan- high /CD138 þ cells demonstrated that these cells are heterogeneous as defined by expression levels of CD19, CD27, CD45 and human leukocyte antigen-DR (Table 3 and representative data in Supplementary Figure 3) . These markers are expressed more highly in less differentiated plasmablasts than in fully differentiated plasma cells.
We fractionated CD38 high /CD138 þ cells based on the expression of CD19 or CD45 in four patient samples and two xenografts (M19 in Supplementary Figure 4) . Fractionated CD45 low/ À or CD19 À CD38 high /CD138 þ cells (6/9 mice) had higher engraftment ability than CD45 high or CD19 þ plasmablasts (0/4) ( Table 4 and M19 in Figure 2d ). These results implicate the presence of transplantable myeloma-initiating cells in more differentiated plasma cells but not in plasmablasts.
DISCUSSION
Primary patient-derived myeloma cells and myeloma cell lines are heterogeneous with respect to surface marker expression, morphology, maturation status, colony-forming ability, proliferation ability and drug resistance. 29, 30 This intratumoral heterogeneity can be explained by the self-renewal and differentiation of a subset of cancer cells called cancer stem cells or tumor-initiating cells. 1 The identification of cancer stem cells has been achieved by examining the engraftment ability of fractionated cancer cells in immunocompromised mice. Therefore, the xenotransplantation of patient myeloma cells is important for cancer stem cell research as well as for preclinical studies of newly developed drugs for multiple myeloma.
Despite previous reports of successful engraftment of patient myeloma cells in mice, 13, 16, 28 a xenotransplantation mouse model that can be simply generated and reliably recapitulate human multiple myeloma has not yet been established. Recently, two newly developed immunocompromised mice (NSG and RAG2 À /gc À ) were shown to successfully engraft various human cancers 8, 20, 31, 32 as well as human umbilical cord blood or mobilized peripheral blood hematopoietic stem cells. 19, 33, 34 Despite their robustness as a xenograft model for these tissue types, these mice were not readily engrafted with myeloma cells injected intravenously or intrafemorally in the current study. This finding suggests that the mouse cellular immune response, which is deficient in these mice, is not the primary mechanism regulating the ability to xenograft human myeloma cells in mice.
The bone marrow microenvironment is critical for plasma cell survival and proliferation. 35, 36 Thus, human fetal bone-bearing mice previously have been shown to engraft myeloma cells, 16, 22, 24 consistent with our results (Table 1 ). In addition, our data demonstrate that the human bone microenvironment is required for human myeloma cell survival and serial transplantation of CD19 À CD138 þ xenografts. This conclusion is based on two observations: (1) the absence of plasma/myeloma cell engraftment in human bone-free mice even after orthotropic intrafemoral injection (Table 1) ; and (2) the preferential migration of engrafted myeloma cells from one human bone graft to another without evidence of engraftment in any mouse hematopoietic tissues (Figures 1d and e) . These data also suggest that the survival factor(s) may be species-specific. For example, IL-6 is a critical factor for multiple myeloma growth and survival, but mouse IL-6 cannot substitute for human IL-6 to induce the proliferation or survival of human cells. 37 Furthermore, the repopulation of human myeloma cells in human bone grafts implies that locally acting factors may have important roles for myeloma cell survival. These locally acting factors may be adhesion molecules or extracellular matrix components human bone marrow, as suggested by the finding by Cassese et al. 38 that both cytokines and adhesiondependent signals from bone marrow stromal cells are required for plasma cell survival. Our studies comparing engraftment of the same patient cells in human bone-free and -bearing mice support the importance of human bone microenvironment for the survival or proliferation of patient primary myeloma cells.
Even Tables 2 and 4 ). Previously, Yaccoby et al. 22 and Huang et al. 24 reported that CD38 high CD45 À and CD138 þ bone marrow cells from myeloma patients successfully engraft in SCIDhu and NOD/SCID-hu mice, respectively. Even though these prior studies did not show a serial transfer of the disease, they strongly suggest that plasma cells or plasmablasts can propagate multiple myeloma in these mouse models. However, another set of studies suggests that B cells may be tumorigenic cells in multiple myeloma. Previous clonotypic analyses of B-lineage cells from patients with multiple myeloma demonstrated that CD19 þ B cells may harbor the same clonal immunoglobulin gene arrangement as myeloma cells, suggesting that the tumor cells may originate from circulating peripheral clonal B cells. [41] [42] [43] Consistent with this idea, Matsui et al. 14, 21 reported that CD20 þ CD27 þ CD138
À memory B cells in the bone marrow and peripheral blood of myeloma patients can initiate myeloma in NOD/SCID mice. This discrepancy may arise from differences in the xenotransplantation models, sample quality or sample preparation methods used in each study. Furthermore, our studies show that CD19 þ CD38 low/ À B cells from myeloma patients are able to engraft in human bone grafts, resulting in the repopulation of polyclonal B cells. As memory B cells have the ability to self-renew, 44 we speculate that bone marrow-residing polyclonal CD19 47 reported that the CD138 À myeloma cells in human myeloma cell lines and in some multiple myeloma patients maintain colony-forming ability. In particular, Hosen et al.
demonstrated that CD138
À myeloma cells from patient bone marrow engrafted mice with rabbit bone grafts better than did their CD138 þ counterparts. However, the hierarchical order of CD138 À and CD138 þ cells in the lineage of myeloma cells still remains to be determined.
In this study, we found that immunocompromised mice bearing fetal human bone grafts are robust engrafters of primary myeloma cells. In addition, CD19
À CD45 low/ À CD38 high /CD138 þ plasma cells, but not CD19 þ B cells or plasmablasts, from multiple myeloma patients enrich for myeloma-initiating cells. In this study, we analyzed the ability of myeloma-initiating cells to engraft in suitable hosts, a measure of the frankly malignant cells in the myeloma. We did not analyze the origins of the first cells that departed from normal hematopoiesis, that is, began the accumulation of genetic and epigenetic events that led to these myeloma-initiating cells, a topic we have addressed previously. 1, 10, 48 These findings indicate the need for future studies on the interaction of myeloma cells and the bone marrow microenvironment to identify signals that are critical for myeloma-initiating cell activity.
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